Alligator Bioscience announced the completion of patient enrolment in the ongoing OPTIMIZE-1 Phase 2 trial of the company's lead asset mitazalimab in 1st line metastatic pancreatic cancer. Thanks to this acceleration in patient enrolment, Alligator confirms it expects to report top-line data in the beginning of First Quarter 2024. The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.158 SEK | +2.30% | +19.88% | +68.07% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+68.07% | 82.38M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in First Quarter 2024